

DAFTAR PUSTAKA

- Afiyanti, Y., Milanti, A., dan Putri, R.H., 2018. Supportive care needs in predicting the quality of life among gynecological cancer patients. *Canadian Oncology Nursing Journal = Revue Canadienne De Nursing Oncologique*, **28**: 22–29.
- Al-Rashideh, A.A. dan Al-Atiyyat, N., 2013. Health Related Quality of Life among Adolescents Surviving Cancer : A Review. *Middle East Journal of Nursing*, **101**: 1–3.
- Anees, M., Malik, M.R., Abbasi, T., Nasir, Z., Hussain, Y., dan Ibrahim, M., 2014. Demographic factors affecting quality of life of hemodialysis patients – Lahore, Pakistan. *Pakistan Journal of Medical Sciences*, **30**: 1123–1127.
- Ariantika, A., Lubis, R., Asfriyati, A., Ashar, T., Nurmaini, N., Soeroso, N.N., dkk., 2024. Assessment of Quality of Life in Advanced-Stage Lung Cancer Patients Using EORTC QLQ-C30 Questionnaire. *Jurnal Respirasi*, **10**: 228–235.
- Arriola, E., Reguart, N., Artal, A., Cobo, M., García-Campelo, R., Esteban, E., dkk., 2015. Management of the adverse events of afatinib: a consensus of the recommendations of the Spanish expert panel. *Future Oncology (London, England)*, **11**: 267–277.
- Aslan, N.A., Hincal, H.O., Elver, Ö., Erol, V., dan Güler, N., 2023. Bosutinib-induced massive pleural effusion: Cross-intolerance with all tyrosine kinase inhibitors. *Journal of Oncology Pharmacy Practice: Official Publication of the International Society of Oncology Pharmacy Practitioners*, **29**: 511–516.
- Aslaner Ak, M., Ertop Doğan, P., dan Sahip, B., 2022. Tyrosine kinase inhibitor nilotinib induced palmoplantar erythrodysesthesia: A rare case. *Journal of Oncology Pharmacy Practice: Official Publication of the International Society of Oncology Pharmacy Practitioners*, **28**: 763–765.
- Asmara, O.D., Tenda, E.D., Singh, G., Pitoyo, C.W., Rumende, C.M., Rajabto, W., dkk., 2023. Lung Cancer in Indonesia. *Journal of Thoracic Oncology*, **18**: 1134–1145.
- Aw, D.C.-W., Tan, E.H., Chin, T.M., Lim, H.L., Lee, H.Y., dan Soo, R.A., 2018. Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities. *Asia-Pacific Journal of Clinical Oncology*, **14**: 23–31.
- Badan Pusat Statistik, 2023. *Statistik Penduduk Lanjut Usia 2023*. Badan Pusat Statistik.
- Berlim, M.T. dan Fleck, M.P.A., 2003. “Quality of life”: a brand new concept for research and practice in psychiatry. *Brazilian Journal of Psychiatry*, **25**: 249–252.
- Bower, J.E., 2014. Cancer-related fatigue—mechanisms, risk factors, and treatments. *Nature Reviews Clinical Oncology*, **11**: 597–609.
- Brueckl, W.M., Reck, M., Schäfer, H., Neben, K., Griesinger, F., Rawluk, J., dkk., 2023. Older patients with *EGFR* mutation-positive non-small cell lung

- cancer treated with afatinib in clinical practice: A subset analysis of the non-interventional GIDEON study. *Journal of Geriatric Oncology*, **14**: 101394.
- Califano, R., Tariq, N., Compton, S., Fitzgerald, D.A., Harwood, C.A., Lal, R., dkk., 2015. Expert Consensus on the Management of Adverse Events from EGFR Tyrosine Kinase Inhibitors in the UK. *Drugs*, **75**: 1335–1348.
- Cárdenas-Fernández, D., Soberanis Pina, P., Turcott, J.G., Chávez-Tapia, N., Conde-Flores, E., Cardona, A.F., dkk., 2023. Management of diarrhea induced by EGFR-TKIs in advanced lung adenocarcinoma. *Therapeutic Advances in Medical Oncology*, **15**: 17588359231192396.
- Carnio, S., Di Stefano, R.F., dan Novello, S., 2016. Fatigue in lung cancer patients: symptom burden and management of challenges. *Lung Cancer: Targets and Therapy*, **7**: 73–82.
- Chan, J.-C., Lee, Y.-H., Liu, C.-Y., Shih, H.-H., Tsay, P.-K., dan Tang, W.-R., 2019. A Correlational Study of Skin Toxicity and Quality of Life in Patients With Advanced Lung Cancer Receiving Targeted Therapy. *Journal of Nursing Research*, **27**: e51.
- Chen, K.-L., Lin, C.-C., Cho, Y.-T., Yang, C.-W., Sheen, Y.-S., Tsai, H.-E., dkk., 2016. Comparison of Skin Toxic Effects Associated With Gefitinib, Erlotinib, or Afatinib Treatment for Non–Small Cell Lung Cancer. *JAMA Dermatology*, **152**: 340–342.
- Chen, Y.-C., Tsai, M.-J., Lee, M.-H., Kuo, C.-Y., Shen, M.-C., Tsai, Y.-M., dkk., 2021. Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations. *BMC Cancer*, **21**: 495.
- Cheng, W.-C., Lin, C.-C., Liao, W.-C., Lin, Y.-C., Chen, C.-H., Chen, H.-J., dkk., 2024. The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study. *BMC Cancer*, **24**: 228.
- Chiou, L.-J., Lin, Y.-Y., dan Lang, H.-C., 2024. Effects of Symptom Burden on Quality of Life in Patients with Lung Cancer. *Current Oncology*, **31**: 6144–6154.
- Cocks, K., Wells, J.R., Johnson, C., Schmidt, H., Koller, M., Oerlemans, S., dkk., 2023. Content validity of the EORTC quality of life questionnaire QLQ-C30 for use in cancer. *European Journal of Cancer*, **178**: 128–138.
- Coleman, J.J. dan Pontefract, S.K., 2016. Adverse drug reactions. *Clinical Medicine*, **16**: 481–485.
- Da M., Shi M., Yan Q., Yang H., Dong Z., dan Wang F., 2021. Skin adverse reactions to afatinib and their correlation with anti-lung cancer efficacy. *Chinese Journal of Dermatology*, 64–67.
- Das, A., Sil, A., Khan, I.A., dan Bandyopadhyay, D., 2023. Dermatological adverse drug reactions to tyrosine kinase inhibitors: a narrative review. *Clinical and Experimental Dermatology*, **48**: 599–608.
- Ding, P.N., Lord, S.J., Gebiski, V., Links, M., Bray, V., Gralla, R.J., dkk., 2017. Risk of Treatment-Related Toxicities from EGFR Tyrosine Kinase Inhibitors: A Meta-analysis of Clinical Trials of Gefitinib, Erlotinib, and Afatinib in

- Advanced EGFR-Mutated Non-Small Cell Lung Cancer. *Journal of Thoracic Oncology*, **12**: 633–643.
- Edwards, I.R. dan Aronson, J.K., 2000. Adverse drug reactions: definitions, diagnosis, and management. *The Lancet*, **356**: 1255–1259.
- Edwards, R.L., Andan, C., Lalla, R.V., Lacouture, M.E., O'Brien, D., dan Sequist, L.V., 2018. Practical Management of Adverse Events Associated with Afatinib. *Clinical journal of oncology nursing*, **22**: 542.
- Fabbrocini, G., Panariello, L., Caro, G., dan Cacciapuoti, S., 2015. Acneiform Rash Induced by EGFR Inhibitors: Review of the Literature and New Insights. *Skin Appendage Disorders*, **1**: 31.
- Farrell, C., Brearley, S.G., Pilling, M., dan Molassiotis, A., 2013. The impact of chemotherapy-related nausea on patients' nutritional status, psychological distress and quality of life. *Supportive Care in Cancer*, **21**: 59–66.
- Fauziah, N. dan Sutrisno, S., 2025. Pengaruh Desentralisasi Fiskal Terhadap Kemiskinan Di Provinsi Daerah Istimewa Yogyakarta Tahun 2017-2023. *E-Jurnal Ekonomi dan Bisnis Universitas Udayana*, 193–206.
- Fayers, P., Aaronson, N., Bjordal, K., Groenvold, M., Curran, D., dan Bottomley, A., 2001. The EORTC QLQ-C30 Scoring Manual (3rd Edition).
- Ferlay, J., Ervick, M., Colombet, M., Pineros, M., Soerjomataram, I., dan Bray, F., 2021. Cancer statistics for the year 2020: An overview. *Int J Cancer*, .
- Florez, N., Kiel, L., Riano, I., Patel, S., DeCarli, K., Dhawan, N., dkk., 2024. Lung Cancer in Women: The Past, Present, and Future. *Clinical Lung Cancer*, **25**: 1–8.
- Freites-Martinez, A., Santana, N., Arias-Santiago, S., dan Viera, A., 2021. Using the Common Terminology Criteria for Adverse Events (CTCAE – Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. *Actas Dermo-Sifiliográficas (English Edition)*, **112**: 90–92.
- Giesinger, J.M., Loth, F.L.C., Aaronson, N.K., Arraras, J.I., Caocci, G., Efficace, F., dkk., 2020. Thresholds for clinical importance were established to improve interpretation of the EORTC QLQ-C30 in clinical practice and research. *Journal of Clinical Epidemiology*, **118**: 1–8.
- Glantz, M.J., Chamberlain, M.C., Liu, Q., Hsieh, C.-C., Edwards, K.R., Van Horn, A., dkk., 2009. Gender disparity in the rate of partner abandonment in patients with serious medical illness. *Cancer*, **115**: 5237–5242.
- Gonzalez, V.J., Beckstead, J., Groer, M., McMillan, S., Ortiz, D., Marrero, S., dkk., 2019. Exploring the Relationship Between Diarrhea and Fatigue That Can Occur During Cancer Treatment: Using Structural Equation Modeling. *Puerto Rico health sciences journal*, **38**: 81–86.
- Ha, S.Y., Choi, S.-J., Cho, J.H., Choi, H.J., Lee, J., Jung, K., dkk., 2015. Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR. *Oncotarget*, **6**: 5465–5474.
- Hadshiew, I.M., Eller, M.S., dan Gilchrest, B.A., 1999. Age-associated decreases in human DNA repair capacity: Implications for the skin. *Age*, **22**: 45–57.
- Han, B., Tjulandin, S., Hagiwara, K., Normanno, N., Wulandari, L., Laktionov, K., dkk., 2017. EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma

- histology: The IGNITE study. *Lung Cancer (Amsterdam, Netherlands)*, **113**: 37–44.
- Hecht, S.S., 2012. Lung Carcinogenesis by Tobacco Smoke. *International journal of cancer. Journal international du cancer*, **131**: 2724.
- Hendriks, L.E., Kerr, K.M., Menis, J., Mok, T.S., Nestle, U., Passaro, A., dkk., 2023. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. *Annals of Oncology*, **34**: 339–357.
- Hendriks, L. E., Kerr, K.M., Menis, J., Mok, T.S., Nestle, U., Passaro, A., dkk., 2023. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆. *Annals of Oncology*, **34**: 339–357.
- Hickok, J.T., Roscoe, J.A., Morrow, G.R., Giguere, J.K., Colman, L.K., dan Malcolm, A., 2006. Effect of nausea vs. vomiting on patients' quality of life during chemotherapy. *Journal of Clinical Oncology*, **24**: 8514–8514.
- Ho, M.-H., So, T.W., Fan, C.L., Chung, Y.T., dan Lin, C.-C., 2024. Prevalence and assessment tools of cancer-related cognitive impairment in lung cancer survivors: a systematic review and proportional meta-analysis. *Supportive Care in Cancer*, **32**: 209.
- Hsu, P.-C., Lee, S.-H., Chiu, L.-C., Lee, C.-S., Wu, C.-E., Kuo, S.C.-H., dkk., 2023. Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan. *Targeted Oncology*, **18**: 195.
- Huang, C.-T., Lin, C.-A., Su, T.-J., Yang, C.-Y., Tsai, T.-H., Hsu, C.-L., dkk., 2023. Monitoring of T790M in plasma ctDNA of advanced EGFR-mutant NSCLC patients on first- or second-generation tyrosine kinase inhibitors. *BMC Cancer*, **23**: 234.
- Hung, L.-J., Chang, J.W.-C., Huang, C.-Y., Fang, Y.-F., Chang, C.-F., Kuo, C.-H.S., dkk., 2023. 578P Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study. *Annals of Oncology*, **34**: S1696.
- Husen, A., Suharti, C., dan Hardian, H., 2016. Hubungan Antara Derajat Nyeri Dengan Tingkat Kualitas Hidup Pasien Kanker Paru Yang Menjalani Kemoterapi. *Jurnal Kedokteran Diponegoro (Diponegoro Medical Journal)*, **5**: 545–557.
- Jeem, Y.A., Pratama, Y.Y., Adnan, M.L., dan Nirwingsyah, N.R., 2022. The Correlation Between the Type of Occupation Toward Blood Pressure and Cholesterol Levels in Individuals with Hypertension. *Journal of Health Sciences*, **15**: 210–217.
- Jeon, K.H., Shin, D.W., Han, K., Kim, D., Yoo, J.E., Jeong, S.-M., dkk., 2020. Female reproductive factors and the risk of lung cancer in postmenopausal women: a nationwide cohort study. *British Journal of Cancer*, **122**: 1417–1424.

- Jiang, T., Su, C., Ren, S., Cappuzzo, F., Rocco, G., Palmer, J.D., dkk., 2018. A consensus on the role of osimertinib in non-small cell lung cancer from the AME Lung Cancer Collaborative Group. *Journal of Thoracic Disease*, **10**:
- Kemmler, G., Holzner, B., Kopp, M., Dünser, M., Margreiter, R., Greil, R., dkk., 1999. Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **17**: 2932–2940.
- Kuan, F.-C., Li, S.-H., Wang, C.-L., Lin, M.-H., Tsai, Y.-H., dan Yang, C.-T., 2016. Analysis of progression-free survival of first-line tyrosine kinase inhibitors in patients with non-small cell lung cancer harboring leu858Arg or exon 19 deletions. *Oncotarget*, **8**: 1343–1353.
- Kumar, Ashwini dan Kumar, Awanish, 2022. Non-small-cell lung cancer-associated gene mutations and inhibitors. *Advances in Cancer Biology - Metastasis*, **6**: 100076.
- Lättman, K., Friman, M., dan Olsson, L.E., 2016. Perceived Accessibility of Public Transport as a Potential Indicator of Social Inclusion | Article | Social Inclusion.
- Laviña, S.M.S., 2024. Measuring Quality of Life through Validated Tools. *Acta Medica Philippina*, **58**: 3–4.
- Levinsen, A.K.G., Dalton, S.O., Andersen, I., Mellempgaard, A., Oksen, M.S., Saltbæk, L., dkk., 2022. Association between Health-Related Quality of Life and Completion of First-Line Treatment among Lung Cancer Patients. *Cancers*, **14**: 3343.
- Liu, J., Yan, S., Du, J., Teng, L., Yang, R., Xu, P., dkk., 2024. Mechanism and treatment of diarrhea associated with tyrosine kinase inhibitors. *Heliyon*, **10**: e27531.
- Liu, L., Wei, Y., Teng, Y., Yan, J., Li, F., dan Chen, Y., 2022. <p>Health-Related Quality of Life and Utility Scores of Lung Cancer Patients Treated with Traditional Chinese Medicine in China</p>. *Patient Preference and Adherence*, **16**: 297–306.
- Łyko, M., Ryguła, A., Kowalski, M., Karska, J., dan Jankowska-Konsur, A., 2024. The Pathophysiology and Treatment of Pyoderma Gangrenosum—Current Options and New Perspectives. *International Journal of Molecular Sciences*, **25**: 2440.
- Manjhi, P.K., Singh, M.P., Kumar, M., Manjhi, P.K., Singh, D.M.P., dan Kumar, M., 2024. Causality, Severity, Preventability and Predictability Assessments Scales for Adverse Drug Reactions: A Review. *Cureus*, **16**: .
- Margareth, I., Siburian, P.K., dan Sitanggang, Y.F., 2024. Dukungan Keluarga terhadap Kualitas Hidup Pasien Kanker Payudara. *MAHESA : Malahayati Health Student Journal*, **4**: 1893–1902.
- Meiller, T.F., Varlotta, S., dan Weikel, D., 2015. Recognition and Management of Oral Mucosal Injury Caused by Mammalian Target of Rapamycin Inhibitors: A Case Series. *Case Reports in Oncology*, **8**: 369–377.

- Michelson, H., Bolund, C., Nilsson, B., dan Brandberg, Y., 2000. Health-related quality of life measured by the EORTC QLQ-C30--reference values from a large sample of Swedish population. *Acta Oncologica (Stockholm, Sweden)*, **39**: 477–484.
- Minegishi, Y., Yamaguchi, O., Sugawara, S., Kuyama, S., Watanabe, S., Usui, K., dkk., 2021. A phase II study of first-line afatinib for patients aged ≥ 75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group trial NEJ027. *BMC Cancer*, **21**: 208.
- Naim, M.J. dan Samad, A., 2025. A Mini-Review on EGFR-Tyrosine Kinase Inhibitors and their Resistance Mechanisms. *Current Pharmaceutical Design*, .
- Napitupulu, E., Nurrochmad, A., Hanafi, A.R., dan Wahyudi, D.T., 2024. Profile of Dermatologic Side Effects of Tyrosine Kinase Inhibitor (EGFR-TKIs) in Lung Cancer Patients. *Jurnal Manajemen Dan Pelayanan Farmasi (Journal of Management and Pharmacy Practice)*, **14**: 214–221.
- Naranjo, C.A., Busto, U., Sellers, E.M., Sandor, P., Ruiz, I., Roberts, E.A., dkk., 1981. A method for estimating the probability of adverse drug reactions. *Clinical Pharmacology & Therapeutics*, **30**: 239–245.
- Niemira, M., Collin, F., Szalkowska, A., Bielska, A., Chwialkowska, K., Reszec, J., dkk., 2019. Molecular Signature of Subtypes of Non-Small-Cell Lung Cancer by Large-Scale Transcriptional Profiling: Identification of Key Modules and Genes by Weighted Gene Co-Expression Network Analysis (WGCNA). *Cancers*, **12**: 37.
- Nirmala, T., Suparta, I.W., dan Anisa, S., 2022. Remitansi Dan Pertumbuhan Ekonomi: Studi Empiris Di 5 Negara ASEAN. *Revenue*, **3**: 251–272.
- Nolte, S., Waldmann, A., Liegl, G., Petersen, M.A., Groenvold, M., dan Rose, M., 2020. Updated EORTC QLQ-C30 general population norm data for Germany. *European Journal of Cancer*, **137**: 161–170.
- Noronha, V., Budukh, A., Chaturvedi, P., Anne, S., Punjabi, A., Bhaskar, M., dkk., 2024. Uniqueness of lung cancer in Southeast Asia. *The Lancet Regional Health - Southeast Asia*, **27**: .
- Noto, S., 2023. Perspectives on Aging and Quality of Life. *Healthcare*, **11**: 2131.
- Nufus, F.F. dan Tatar, F.M., 2017. Hubungan Antara Optimisme Dengan Kualitas Hidup Pada Pasien Kanker. *Psikoislamedia: Jurnal Psikologi*, **2**: 65–74.
- Orindi, O.T., Aduda, D.S.O., dan Amimo, F.A., 2021. Socio-Demographic Characteristics Associated with Quality of Life-Scores among Palliative Care Cancer Patients in Kenya. *Journal of Community Medicine & Public Health*, .
- Østertun Geirdal, A.K., Leung, J., Price, D., Kabelenga, I., Lamph, G., Thygesen, H., dkk., 2024. Associations Between Demographic Variables, Psychosocial Health, Quality of Life, and Happiness in the Context of COVID-19. *Applied Research in Quality of Life*, **19**: 603–617.
- Papavassiliou, K.A., Sofianidi, A.A., Gogou, V.A., Anagnostopoulos, N., dan Papavassiliou, A.G., 2024. P53 and Rb Aberrations in Small Cell Lung Cancer (SCLC): From Molecular Mechanisms to Therapeutic Modulation. *International Journal of Molecular Sciences*, **25**: 2479.

- Park, K., Tan, E.-H., O'Byrne, K., Zhang, L., Boyer, M., Mok, T., dkk., 2016. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. *The Lancet Oncology*, **17**: 577–589.
- Patel, R., 2014. EGFR Signaling and its inhibition by EGFR inhibitors in NSCLC. *International Journal of Applied Sciences and Biotechnology*, **2**: 375–388.
- Permata, A., Perwitasari, D.A., Candradewi, S.F., Septiantoro, B.P., dan Purba, F.D., 2022. Penilaian Kualitas Hidup Pasien Kanker Nasofaring Dengan Menggunakan EORTC QLQ-C30 di RSUP dr. Kariadi Semarang. *JPSCR: Journal of Pharmaceutical Science and Clinical Research*, **7**: 39–47.
- Perwitasari, D., Purba, F., Candradewi, S., Marwin, M., Permata, A., Ulfa Faza, M., dkk., 2023. Mapping EORTC-QLQ-C30 onto EQ-5D-5L Index in Indonesian Cancer Patients. *Asian Pacific Journal of Cancer Prevention*, **24**: 1125–1130.
- Perwitasari, D.A., Atthobari, J., Dwiprahasto, I., Hakimi, M., Gelderblom, H., Putter, H., dkk., 2011. Translation and Validation of EORTC QLQ-C30 into Indonesian Version for Cancer Patients in Indonesia. *Japanese Journal of Clinical Oncology*, **41**: 519–529.
- Perwitasari, D.A., Atthobari, J., Mustofa, M., Dwiprahasto, I., Hakimi, M., Gelderblom, H., dkk., 2012. Impact of Chemotherapy-Induced Nausea and Vomiting on Quality of Life in Indonesian Patients With Gynecologic Cancer. *International Journal of Gynecological Cancer*, **22**: 139–145.
- Pinheiro, G., Pereira, T., Dias, C., Freitas, C., Hespanhol, V., Costa, J.L., dkk., 2020. Identifying relationships between imaging phenotypes and lung cancer-related mutation status: EGFR and KRAS. *Scientific Reports*, **10**: 3625.
- Pluzański, A. dan Piórek, A., 2016. Side effects of tyrosine kinase inhibitors — management guidelines. *Oncology in Clinical Practice*, **12**: 113–118.
- Poh, M.E., Chai, C.S., Liam, C.K., Ho, G.F., Pang, Y.K., Hasbullah, H.H., dkk., 2024. Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice? *Translational Lung Cancer Research*, **13**: .
- Polanski, J., Jankowska-Polanska, B., Rosinczuk, J., Chabowski, M., dan Szymanska-Chabowska, A., 2016. Quality of life of patients with lung cancer. *OncoTargets and therapy*, **9**: 1023.
- Potthoff, K., Hofheinz, R., Hassel, J.C., Volkenandt, M., Lordick, F., Hartmann, J.T., dkk., 2011. Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. *Annals of Oncology*, **22**: 524–535.
- Pramesti, D., Andini, N.L.P.J., Raharjo, D.A.K., dan Dwipayana, A.D., 2024. Efektivitas Penggunaan Moda Transportasi Umum Dengan Kendaraan Pribadi. *Indonesian Journal of Multidisciplinary on Social and Technology*, **2**: 6–16.
- Prapa, P., Papathanasiou, I.V., Bakalis, V., Malli, F., Papagiannis, D., dan Fradelos, E.C., 2021. Quality of Life and Psychological Distress of Lung Cancer Patients Undergoing Chemotherapy. *World Journal of Oncology*, **12**: 61.

- Putri, T.A.R.K., 2017. Status Emosional Dan Kualitas Hidup Pada Pasien Miastenia Gravis. *Jurnal Keperawatan Komprehensif (Comprehensive Nursing Journal)*, **3**: 111–120.
- Quadrelli, S., Lyons, G., Colt, H., Chimondeguy, D., dan Buero, A., 2015. Clinical Characteristics and Prognosis of Incidentally Detected Lung Cancers. *International Journal of Surgical Oncology*, **2015**: 287604.
- Rasca, S. dan Saeed, N., 2022. Exploring the factors influencing the use of public transport by commuters living in networks of small cities and towns. *Travel Behaviour and Society*, **28**: 249–263.
- Ratna, R., Supadmi, W., dan Yuniarti, E., 2021. Kualitas Hidup Pasien Kanker Rawat Jalan yang Menjalani Kemoterapi di RSUD Kota Yogyakarta. *Majalah Farmaseutik*, **17**: .
- Recuero, J.K., Fitz, J.R., Pereira, A.A., dan Bonamigo, R.R., 2023. EGFR inhibitors: clinical aspects, risk factors and biomarkers for acneiform eruptions and other mucosal and cutaneous adverse effects. *Anais Brasileiros de Dermatologia*, **98**: 429.
- Reynaldi, A., W, Y.T., dan Adiningsih, D., 2020. Gambaran Kualitas Hidup Pasien Kanker Paru Stadium Lanjut di RS Paru Dr. H. A. Rotinsulu Bandung. *Journal of Nursing Care*, **3**: .
- Riccetti, N., Blettner, M., Taylor, K., Wehler, B., Gohrbandt, B., Nestle, U., dkk., 2022. Quality of life in lung cancer survivors treated with tyrosine-kinase inhibitors (TKI): results from the multi-centre cross-sectional German study LARIS. *Journal of Cancer Research and Clinical Oncology*, **148**: 1943–1953.
- Ruano-Raviña, A., Provencio, M., Calvo de Juan, V., Carcereny, E., Moran, T., Rodriguez-Abreu, D., dkk., 2020. Lung cancer symptoms at diagnosis: results of a nationwide registry study. *ESMO Open*, **5**: e001021.
- Sari, L. dan Purwanto, P., 2017. Mutasi EGFR pada Non-Small Cell Lung Cancer di Rumah Sakit Kanker “Dharmais.” *Indonesian Journal of Cancer*, **10**: 131.
- Schultheis, K., Hofheinz, R.-D., Gencer, D., Blunk, J.A., dan Benrath, J., 2013. Quality of Life and Symptom Evaluation in Daily Oncology Practice: A Survey of 150 Patients with Advanced Gastrointestinal Tumours Receiving Palliative Chemotherapy. *Onkologie*, **36**: 33–37.
- Siegel, R.L., Giaquinto, A.N., dan Jemal, A., 2024. Cancer statistics, 2024. *CA: A Cancer Journal for Clinicians*, **74**: 12–49.
- Simmons, C.P.L., MacLeod, N., dan Laird, B.J.A., 2012. Clinical Management of Pain in Advanced Lung Cancer. *Clinical Medicine Insights. Oncology*, **6**: 331–346.
- Snyder, C.F., Blackford, A.L., Okuyama, T., Akechi, T., Yamashita, H., Toyama, T., dkk., 2013. Using the EORTC QLQ-C30 in Clinical Practice for Patient Management: Identifying Scores Requiring a Clinician’s Attention. *Quality of life research: an international journal of quality of life aspects of treatment, care and rehabilitation*, **22**: 10.1007/s11136-013-0387–8.

- Stein, A., Voigt, W., dan Jordan, K., 2010. Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. *Therapeutic Advances in Medical Oncology*, **2**: 51–63.
- Stephanie SM dan Diedra LB, 2019. *Drug Information Handbook for Oncology*, 16th ed. Wolters Kluwer.
- Subarkah, P., Solikhatin, S.A., Darmayanti, I., Ikhsan, A.N., Hidayah, D.U., dan Anjani, R.M., 2022. Prediction of Education Level in Population Data Using Naïve Bayes Algorithm. *TIERS Information Technology Journal*, **3**: 69–75.
- Takamochi, K., Oh, S., dan Suzuki, K., 2013. Differences in EGFR and KRAS mutation spectra in lung adenocarcinoma of never and heavy smokers. *Oncology Letters*, **6**: 1207–1212.
- Tamási, L., Horváth, K., Kiss, Z., Bogos, K., Ostoros, G., Müller, V., dkk., 2021. Age and Gender Specific Lung Cancer Incidence and Mortality in Hungary: Trends from 2011 Through 2016. *Pathology and Oncology Research*, **27**: 598862.
- Tang, W.-C., 2023. 581P The associations between afatinib-related adverse events and survival outcomes in patients with lung cancer. *Annals of Oncology*, **34**: S1697.
- Taufik, H., Soeroso, N., Tarigan, S., dan Mutiara, E., 2020. Proportion of Mutation of Epidermal Growth Factor Receptor (EGFR) Genes from Tissue Biopsy and Liquid Biopsy ctDNA in Lung Adenocarcinoma. *Jurnal Respirologi Indonesia*, **40**: 150–155.
- Teo, Y.X. dan Walsh, S.A., 2016. Severe adverse drug reactions. *Clinical Medicine*, **16**: 79–83.
- Thandra, K.C., Barsouk, Adam, Saginala, K., Aluru, J.S., dan Barsouk, Alexander, 2021. Epidemiology of lung cancer. *Contemporary Oncology*, **25**: 45.
- Thomas, A., Rajan, A., dan Giaccone, G., 2012. Tyrosine Kinase Inhibitors in Lung Cancer. *Hematology/Oncology Clinics of North America*, **26**: 589.
- Tseng, L.-C., Chen, K.-H., Wang, C.-L., dan Weng, L.-C., 2020. Effects of tyrosine kinase inhibitor therapy on skin toxicity and skin-related quality of life in patients with lung cancer: An observational study. *Medicine*, **99**: e20510.
- Udupa, K., Rajendranath, R., dan Sagar, T.G., 2017. Comparison study of quality of life in advanced lung cancer patients on tyrosine kinase inhibitor and platinum doublet chemotherapy. *Indian Journal of Cancer*, **54**: 161.
- Ueda, Y., Suzuki, H., Kondo, Y., Okamoto, N., Kumode, A., Usui, N., dkk., 2016. Risk Factors of Afatinib Induced Diarrhea: A Retrospective Study. *Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences)*, **42**: 670–677.
- Um, S.H., Abuzgaia, A., dan Rieder, M., 2023. Comparison of the Liverpool Causality Assessment Tool vs. the Naranjo Scale for predicting the likelihood of an adverse drug reaction: A retrospective cohort study. *British Journal of Clinical Pharmacology*, **89**: 2407–2412.
- Villa, A. dan Kuten-Shorrer, M., 2023. Pathogenesis of Oral Toxicities Associated with Targeted Therapy and Immunotherapy. *International Journal of Molecular Sciences*, **24**: 8188.

- Wahyuni, P., Miro, S., dan Kurniawan, E., 2018. Hubungan Lama Menjalani Hemodialisis dengan Kualitas Hidup Pasien Penyakit Ginjal Kronik dengan Diabetes Melitus di RSUP Dr. M Djamil Padang. *Jurnal Kesehatan Andalas*, **7**: 480–485.
- Wang, A., Ling, Z., Yang, Z., Kiela, P.R., Wang, T., Wang, C., dkk., 2015. Gut Microbial Dysbiosis May Predict Diarrhea and Fatigue in Patients Undergoing Pelvic Cancer Radiotherapy: A Pilot Study. *PLoS ONE*, **10**: e0126312.
- Wiffen, P., Mitchell, M., Snelling, M., Stoner, N., Wiffen, P., Mitchell, M., dkk. (Editor), 2017. Adverse drug reactions and drug interactions, dalam: *Oxford Handbook of Clinical Pharmacy*. Oxford University Press, hal. 0.
- Wind, S., Schmid, M., Erhardt, J., Goeldner, R.-G., dan Stopfer, P., 2013. Pharmacokinetics of afatinib, a selective irreversible ErbB family blocker, in patients with advanced solid tumours. *Clinical Pharmacokinetics*, **52**: 1101–1109.
- Wirth, S.M., 2015. Afatinib in Non–Small Cell Lung Cancer. *Journal of the Advanced Practitioner in Oncology*, **6**: 448.
- Witherspoon, J.N., Wagner, L., Rademaker, A., West, D.P., Rosenbaum, S.E., dan Lacouture, M.E., 2008. Correlation of patient characteristics and NCI-Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 grading with dermatology-related quality of life (QoL) in patients with EGFR inhibitor-induced rash. *Journal of Clinical Oncology*, **26**: 9559–9559.
- World Health Organization, 2012. WHOQOL User Manual. *WHO*, **03**: 11.
- Wu, S.-G., Yu, C.-J., Yang, J.C.-H., dan Shih, J.-Y., 2020. The effectiveness of afatinib in patients with lung adenocarcinoma harboring complex epidermal growth factor receptor mutation. *Therapeutic Advances in Medical Oncology*, **12**: 1758835920946156.
- Wu, Y.-L., Zhou, C., Hu, C.-P., Feng, J., Lu, S., Huang, Y., dkk., 2014. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial. *The Lancet Oncology*, **15**: 213–222.
- Yang, J.C.-H., Reguart, N., Barinoff, J., Köhler, J., Uttenreuther-Fischer, M., Stammberger, U., dkk., 2013. Diarrhea associated with afatinib: an oral ErbB family blocker. *Expert Review of Anticancer Therapy*, **13**: 729–736.
- Yang, W., Lu, Y., Wu, Z., dan Niu, J., 2023. Toxic epidermal necrosis associated with afatinib: A case report and literature review. *Frontiers in Oncology*, **12**: .
- Yeo, W., Mo, F.K.F., Yip, C.C.H., Yeo, V.A., Li, L., Lau, T.K.H., dkk., 2021. Quality of Life Associated with Nausea and Vomiting from Anthracycline-Based Chemotherapy: A Pooled Data Analysis from Three Prospective Trials. *The Oncologist*, **26**: e2288–e2296.
- Yuan, C. dan Wang, B., 2023. Acneiform eruption induced by molecularly targeted agents in antineoplastic therapy: A review. *Journal of Cosmetic Dermatology*, **22**: 2150–2157.

- Yuan, T., Zhou, Y., Wang, T., Li, Y., dan Wang, Y., 2024. Impact research of pain nursing combined with hospice care on quality of life for patients with advanced lung cancer. *Medicine*, **103**: e37687.
- Zhang, J., IJzerman, M.J., Oberoi, J., Karnchanachari, N., Bergin, R.J., Franchini, F., dkk., 2022. Time to diagnosis and treatment of lung cancer: A systematic overview of risk factors, interventions and impact on patient outcomes. *Lung Cancer (Amsterdam, Netherlands)*, **166**: 27–39.
- Zhang, P., Mao, R., Zhang, C., Qiu, Y., dan Chen, M., 2023. Gastrointestinal injury induced by immunomodulators: A review article. *Therapeutic Advances in Gastroenterology*, **16**: 17562848231158549.
- Zhang, Y., Vaccarella, S., Morgan, E., Li, M., Etzeberria, J., Chokunonga, E., dkk., 2023. Global variations in lung cancer incidence by histological subtype in 2020: a population-based study. *The Lancet Oncology*, **24**: 1206–1218.
- Zhao, Y., Cheng, B., Chen, Zisheng, Li, J., Liang, H., Chen, Y., dkk., 2021. Toxicity profile of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung cancer: A systematic review and network meta-analysis. *Critical Reviews in Oncology/Hematology*, **160**: 103305.
- Zub, V., Tolstanov, O., Kotuza, A., dan Manzhali, E., 2023. Quality of life of lung cancer patients. *Current Issues in Pharmacy and Medical Sciences*, **36**: 145–150.